Jazz Pharmaceuticals PLC - Asset Resilience Ratio
Jazz Pharmaceuticals PLC (JAZZ) has an Asset Resilience Ratio of 9.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Jazz Pharmaceuticals PLC for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Jazz Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. See shareholders equity of Jazz Pharmaceuticals PLC for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jazz Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see JAZZ stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.05 Billion | 9.01% |
| Total Liquid Assets | $1.05 Billion | 9.01% |
Asset Resilience Insights
- Limited Liquidity: Jazz Pharmaceuticals PLC maintains only 9.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jazz Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Jazz Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Jazz Pharmaceuticals PLC (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Jazz Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.01% | $1.05 Billion | $11.66 Billion | +4.18pp |
| 2024-12-31 | 4.83% | $580.00 Million | $12.01 Billion | +3.78pp |
| 2023-12-31 | 1.05% | $120.00 Million | $11.39 Billion | +0.78pp |
| 2022-12-31 | 0.28% | $30.00 Million | $10.84 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $12.30 Billion | -- |
| 2020-12-31 | 16.45% | $1.07 Billion | $6.54 Billion | +8.50pp |
| 2019-12-31 | 7.94% | $440.00 Million | $5.54 Billion | -1.95pp |
| 2018-12-31 | 9.90% | $515.00 Million | $5.20 Billion | +5.70pp |
| 2017-12-31 | 4.20% | $215.00 Million | $5.12 Billion | +2.95pp |
| 2016-12-31 | 1.25% | $60.00 Million | $4.80 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $3.36 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $3.34 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $2.24 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.97 Billion | -- |
| 2011-12-31 | 29.90% | $75.82 Million | $253.57 Million | +29.61pp |
| 2010-12-31 | 0.29% | $400.00K | $135.73 Million | -2.49pp |
| 2009-12-31 | 2.78% | $2.99 Million | $107.40 Million | +1.93pp |
| 2008-12-31 | 0.85% | $1.00 Million | $117.50 Million | -4.93pp |
| 2007-12-31 | 5.78% | $12.00 Million | $207.55 Million | +5.65pp |
| 2006-12-31 | 0.13% | $275.00K | $214.57 Million | -0.05pp |
| 2005-12-31 | 0.18% | $300.00K | $164.78 Million | -- |
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more